Noticias de NVO_US
Noticias del mercado
Últimas noticias sobre NVO_US — 665 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
With trial win, Novo Nordisk eyes adolescent diabetes approval for oral semaglutide
Is Novo Nordisk's 72% Crash a Generational Buying Opportunity or a Value Trap?
Novo Nordisk (NVO) Stock Jumps on Diabetes Pill Trial Win in Children
Novo to launch Ozempic pill for children after late-stage trial win
Novo Nordisk aims for US approval for Ozempic for kids
Novo Nordisk to Seek Approval for Pill to Treat Diabetes in Young Patients
Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes
Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes
En la sesión de negociación más reciente, Novo Nordisk (NVO) cerró a 38,52 dólares, lo que indica un cambio del -1,61% con respecto al día de negociación anterior.
Biotech Investor Alex Karnal: GLP-1 Drugs Signal 'Trillion-Dollar Revolution' in Public Health
Delay in Medicare pilot for obesity drugs may not hurt near-term demand, analysts say
Experts see an ethical turning point at Novo following a new partnership: “It's horrifying”
Página 28 de 34
